A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

23/03/2015 - 2 minutes

University of Copenhagen released a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. The vaccine candidate contains a malaria antigen made with ExpreS2ion Biotechnologies’ protein expression technology, ExpreS2.

This vaccine candidate results from many years of research done by Professor Ali Salanti and his team at the Department of Immunology and Microbiology at the University of Copenhagen. The work leading to the release of the testing lot of this vaccine has been funded by the Danish Advanced Technology Foundation (HTF, now Innovation Fund) the European Vaccine Initiative (EVI) and the Framework 7 European Union program.

It is the first time that a university in Denmark has conceived and produced a vaccine, and this has only been achieved because of the very close cooperation within the consortium that includes ExpreS2ion and the University,” commented Professor Salanti.

More than 30 variants of the complex malaria antigen that forms part of this vaccine were produced by ExpreS2ion to enable Professor Salanti’s team to perform the needed tests to select the most promising vaccine candidate.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member